A practical reference on metabolic modulator: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-09-26. Anything still debated is marked as such rather than presented as settled.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine in major jurisdictions | Sold as a research chemical; legal status varies |
| Anti-doping status | Prohibited by the World Anti-Doping Agency | Listed under non-approved substances or related category |
| Typical analytical method | LC-MS/MS | Used for detection and confirmation in biological samples |
| Storage temperature | −20 °C or lower for solid | Desiccated and protected from light |
| Common solution solvents | DMSO; ethanol | Aqueous solubility is limited |
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
At the same time, the need for such a system was becoming increasingly pressing. In 1932, Winston Churchill and his friend, confidant and scientific advisor Frederick Lindemann travelled by car in Europe, where they saw the rapid rebuilding of the German aircraft industry. It was in November of that year that Stanley Baldwin gave his famous speech, stating that "The bomber will always get through". In the early summer of 1934, the RAF carried out large-scale exercises with up to 350 aircraft. The forces were split, with bombers attempting to attack London, while fighters, guided by the Observer Corps, attempted to stop them. The results were dismal. In most cases, the vast majority of the bombers reached their target without ever seeing a fighter. To address the one-sided results, the RAF gave increasingly accurate information to the defenders, eventually telling the observers where and when the attacks would be taking place. Even then, 70 per cent of the bombers reached their targets unhindered. The numbers suggested any targets in the city would be destroyed. Squadron Leader P. R. Burchall summed up the results by noting that "a feeling of defencelessness and dismay, or at all events of uneasiness, has seized the public." In November, Churchill gave a speech on "The threat of Nazi Germany" in which he pointed out that the Royal Navy could not protect Britain from an enemy who attacked by air. Through the early 1930s, a debate raged within British military and political circles about strategic airpower.
From the Cologne War through the Thirty Years' Wars (1618–1648), religious conflict devastated German lands and significantly reduced the population. The Peace of Westphalia ended religious warfare among the Imperial Estates. The legal system initiated by a series of Imperial Reforms (approximately 1495–1555) provided for considerable local autonomy and a stronger Imperial Diet. The House of Habsburg held the imperial crown from 1438 until the death of Charles VI in 1740. Following the War of the Austrian Succession and the Treaty of Aix-la-Chapelle, Charles VI's daughter Maria Theresa ruled as empress consort when her husband, Francis I, became emperor. From 1740, dualism between the Austrian Habsburg monarchy and the Kingdom of Prussia dominated German history. In 1772, 1793, and 1795, Prussia and Austria, along with the Russian Empire, agreed to the Partitions of Poland. During the period of the French Revolutionary Wars, the Napoleonic era and the subsequent final meeting of the Imperial Diet, most of the Free Imperial Cities were annexed by dynastic territories; the ecclesiastical territories were secularised and annexed. In 1806, the Imperium was dissolved; France, Russia, Prussia, and the Habsburgs (Austria) competed for hegemony in the German states during the Napoleonic Wars.
There are few native natural predators of adult emus still extant. Early in its species history it may have faced numerous terrestrial predators now extinct, including the giant lizard Megalania, the thylacine, and possibly other carnivorous marsupials, which may explain their seemingly well-developed ability to defend themselves from terrestrial predators. The main predator of emus today is the dingo, which was originally introduced by Aboriginals thousands of years ago from a stock of semi-domesticated wolves. Dingoes try to kill the emu by attacking the head. The emu typically tries to repel the dingo by jumping into the air and kicking or stamping the dingo on its way down. The emu jumps as the dingo barely has the capacity to jump high enough to threaten its neck, so a correctly timed leap to coincide with the dingo's lunge can keep its head and neck out of danger. Despite the potential prey-predator relationship, the presence of predaceous dingoes does not appear to heavily influence emu numbers, with other natural conditions just as likely to cause mortality. Wedge-tailed eagles are the only avian predator capable of attacking fully-grown emus, though are perhaps most likely to take small or young specimens. The eagles attack emus by swooping downwards rapidly and at high speed and aiming for the head and neck. In this case, the emu's jumping technique as employed against the dingo is not useful. The birds try to target the emu in the open ground so that it cannot hide behind obstacles.
Sources: en.wikipedia.org
Dutch Bros Inc., originally written Dutch Bros. (with a period at the end), is a publicly held drive-through coffee chain in the United States. Founded in 1992 by Dane and Travis Boersma, it is headquartered in Tempe, Arizona, after having been based in Grants Pass, Oregon, for many years prior to 2025. It has company-owned and franchise locations primarily located in the Western United States, although the company has expanded as far east as Orlando, Florida.
A large number of medications are potent inhibitors of CYP2D6. Some types of medications known to inhibit CYP2D6 include certain SSRIs and tricyclic antidepressants, some antipsychotics, and the commonly available antihistamine diphenhydramine. Therefore, the potential for interactions exists between dextromethorphan and medications that inhibit this enzyme, particularly in slow metabolizers. Dextromethorphan is also metabolized by CYP3A4. N-demethylation is primarily accomplished by CYP3A4, contributing to at least 90% of the MEM formed as a primary metabolite of dextromethorphan. A number of other CYP enzymes are implicated as minor pathways of dextromethorphan metabolism. CYP2D6 is more effective than CYP3A4 at N-demethylation of dextromethorphan, but since the average individual has a much lower CYP2D6 content in the liver compared to CYP3A4, most N-demethylation of dextromethorphan is catalyzed by CYP3A4.
Lipostatic hypothesis: This hypothesis holds that adipose tissue produces a humoral signal that is proportionate to the amount of fat and acts on the hypothalamus to decrease food intake and increase energy output. It has been evident that a hormone leptin acts on the hypothalamus to decrease food intake and increase energy output. Gutpeptide hypothesis: gastrointestinal hormones like Grp, glucagons, CCK and others claimed to inhibit food intake. The food entering the gastrointestinal tract triggers the release of these hormones, which act on the brain to produce satiety. The brain contains both CCK-A and CCK-B receptors. Glucostatic hypothesis: The activity of the satiety center in the ventromedial nuclei is probably governed by the glucose utilization in the neurons. It has been postulated that when their glucose utilization is low and consequently when the arteriovenous blood glucose difference across them is low, the activity across the neurons decrease. Under these conditions, the activity of the feeding center is unchecked and the individual feels hungry. Food intake is rapidly increased by intraventricular administration of 2-deoxyglucose therefore decreasing glucose utilization in cells. Thermostatic hypothesis: According to this hypothesis, a decrease in body temperature below a given set-point stimulates appetite, whereas an increase above the set-point inhibits appetite.
== External links == Official website Example SWAPO Party Youth League web page. "Latest from the SPYL Frontlines". spyl.swapo.party. SWAPO Party Youth League. 28 August 2012. Archived from the original on 28 August 2012. Retrieved 7 November 2024.
Sources: en.wikipedia.org
== Uses == Nylon was first used commercially in a nylon-bristled toothbrush in 1938, followed more famously in women's stockings or "nylons" which were shown at the 1939 New York World's Fair and first sold commercially in 1940. Its use increased dramatically during World War II, when the need for fabrics increased dramatically.
BrO3− + 5 Br− + 6 H+ → 3 Br2 + 3 H2O There were many failed attempts to obtain perbromates and perbromic acid, leading to some rationalisations as to why they should not exist, until 1968 when the anion was first synthesised from the radioactive beta decay of unstable 83SeO42−. Today, perbromates are produced by the oxidation of alkaline bromate solutions by fluorine gas. Excess bromate and fluoride are precipitated as silver bromate and calcium fluoride, and the perbromic acid solution may be purified. The perbromate ion is fairly inert at room temperature but is thermodynamically extremely oxidising, with extremely strong oxidising agents needed to produce it, such as fluorine or xenon difluoride. The Br–O bond in BrO4− is fairly weak, which corresponds to the general reluctance of the 4p elements arsenic, selenium, and bromine to attain their group oxidation state, as they come after the scandide contraction characterised by the poor shielding afforded by the radial-nodeless 3d orbitals.
The first pass effect (FPE), also known as first-pass metabolism (FPM) or presystemic metabolism, is a phenomenon of drug metabolism at a specific location in the body which leads to a reduction in the concentration of the active drug before it reaches the site of action or systemic circulation. The effect is most associated with orally administered medications, but some drugs still undergo first-pass metabolism even when delivered via an alternate route (e.g., IV, IM, etc.). During this metabolism, drug is lost during the process of absorption which is generally related to the liver and gut wall. The liver is the major site of first pass effect; however, it can also occur in the lungs, vasculature or other metabolically active tissues in the body. Notable drugs that experience a significant first pass effect are buprenorphine, chlorpromazine, cimetidine, diazepam, ethanol (drinking alcohol), imipramine, insulin, lidocaine, midazolam, morphine, pethidine, propranolol, and tetrahydrocannabinol (THC). First-pass metabolism is not to be confused with phase I metabolism, which is a separate process.
Sources: en.wikipedia.org
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.
Laboratories typically use LC-MS/MS to detect SR9009 and related compounds in urine or blood. The method is sensitive but depends on sample collection timing. Confirmatory analysis follows quality-control procedures.
Solid material is generally kept cold, dry, and protected from light. Solutions are often stored in sealed containers at low temperature. Stability beyond recommended periods is not well documented.
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.